 - be receiving at least four cycles of anthracycline-based chemotherapy which may include: doxorubicincyclophosphamide AC,5-fluorouracildoxorubicincyclophosphamide FAC, fluoruracilepirubicincyclophosphamide FEC or dose dense chemotherapy regimen AC every two weeks as their agents for neoadjuvant or adjuvant chemotherapy 